Published • loading... • Updated
ConcertAI enhances CancerLinQ Suite for oncology trials
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
ConcertAI Expands CancerLinQ Suite with AI-Driven Trial Matching
What You Should Know Healthcare intelligence leader ConcertAI has unveiled major AI-driven enhancements to its CancerLinQ Suite at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.Powered by Cara, ConcertAI’s proprietary agentic AI platform, the suite automatically parses structured and unstructured data on a weekly basis across a massive footprint of 13 million patient records.The upgraded TriaLinQ module automates patient s…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
